Next-Generation TCRm TCE Therapeutics: A Paradigm Shift in Solid Tumor Immunotherapy
Time: 4:30 pm
day: Day 1
Details:
- TCRm targeting of undruggable intracellular proteins presents a unique opportunity for immunotherapy.
- T cell engagers (TCEs) are emerging as effective therapies for solid tumors.
- The Keyway TCRm Discovery platform provides an end-to-end workflow, delivering next-generation immunotherapies from target identification to clinical application
